Immunocore (NASDAQ:IMCR) Stock Moved Down to Strong Sell by Zacks Research

Immunocore (NASDAQ:IMCR) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Monday, Zacks reports.

Other analysts also recently issued reports about the company. HC Wainwright reduced their target price on Immunocore from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Tuesday. Wall Street Zen lowered Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a report on Monday, July 13th. Morgan Stanley set a $43.00 target price on shares of Immunocore in a report on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $53.00.

Immunocore Stock Performance

Shares of Immunocore stock opened at $32.38 on Monday. The company has a quick ratio of 4.44, a current ratio of 4.62 and a debt-to-equity ratio of 0.94. Immunocore has a twelve month low of $27.50 and a twelve month high of $40.71. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -49.81 and a beta of 0.82. The company’s fifty day moving average is $31.46 and its 200 day moving average is $31.70.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Friday, November 6th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). The company had revenue of $102.22 million during the quarter, compared to analyst estimates of $152.09 million. Immunocore had a negative net margin of 7.48% and a negative return on equity of 7.96%. Sell-side analysts forecast that Immunocore will post -0.04 EPS for the current year.

Hedge Funds Weigh In On Immunocore

Several large investors have recently modified their holdings of IMCR. GAMMA Investing LLC lifted its stake in shares of Immunocore by 202.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock valued at $61,000 after buying an additional 1,286 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Immunocore during the 3rd quarter valued at $72,000. Juncture Wealth Strategies LLC purchased a new stake in shares of Immunocore during the third quarter worth $207,000. denkapparat Operations GmbH purchased a new stake in shares of Immunocore during the second quarter worth $209,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Immunocore by 27.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,252 shares of the company’s stock worth $285,000 after acquiring an additional 1,975 shares during the period. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Key Immunocore News

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Shares crossed above their 200-day moving average, a potentially supportive technical signal, despite the earnings miss referenced in the report. Immunocore shares cross above 200-day moving average
• Positive Sentiment: HC Wainwright maintained its Buy rating and an $80 price target—about 147% above the cited $32.38 share price—though the target was reduced from $100. HC Wainwright rating and price target
• Neutral Sentiment: Immunocore presented at the Society for Immunotherapy of Cancer’s 2026 annual meeting; the available article is a slideshow and does not detail specific new clinical findings. SITC 2026 presentation slideshow
• Negative Sentiment: HC Wainwright trimmed its 2027 EPS forecasts for Q1 ($0.17 from $0.18), Q2 ($0.26 from $0.29) and full-year 2027 ($1.34 from $1.36). It raised its Q4 estimate to $0.52 from $0.49, but the overall revisions were lower.
• Negative Sentiment: The cut in HC Wainwright’s price target from $100 to $80 may weigh on sentiment, even with its Buy rating retained.

Immunocore Company Profile

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.